A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01227889
First received: October 21, 2010
Last updated: June 12, 2014
Last verified: June 2014
Results First Received: June 6, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Cancer
Interventions: Drug: GSK2118436
Drug: Dacarbazine (DTIC)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
In the Randomized Phase, participants receiving GSK2118436 150 milligrams were treated for up to 16.4 months, and participants receiving dacarbazine 1000 milligrams per meters squared were treated for up to 12.2 months.

Reporting Groups
  Description
GSK2118436 150 mg BID Participants (par.) were randomly assigned to receive oral GSK2118436 150 milligrams (mg) twice a day (BID). Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until disease progression (DP), death, the occurrence of an unacceptable adverse event (AE), or withdrawal from the study. Participants who experienced investigator-reported DP but were benefitting from study treatment were permitted to continue GSK2118436 treatment upon approval of the GlaxoSmithKline Medical Monitor.
DTIC 1000 mg/m^2 in RP; GSK2118436 in Crossover Phase In the RP, par. received intravenous (IV) Dacarbazine (DTIC) 1000 mg per meters squared (mg/m^2) every 3 weeks. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Par. continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study. Par. who received DTIC in the RP and experienced DP had the option, at the discretion of the Investigator, of receiving GSK2118436 150 mg BID in the Crossover Phase. Par. who permanently discontinued DTIC treatment due to an AE, withdrawal of consent, or for any reason other than DP were not eligible for crossover to GSK2118436. Crossover par. continued on GSK2118436 until further DP was noted. After DP on GSK2118436, par. were followed for response, progression, survival, and further anti-cancer therapy.

Participant Flow for 2 periods

Period 1:   Randomized Phase (RP)
    GSK2118436 150 mg BID     DTIC 1000 mg/m^2 in RP; GSK2118436 in Crossover Phase  
STARTED     187     63  
In Follow-up     49     10  
Ongoing     53     2  
Crossed Over     0     36  
COMPLETED     0     0  
NOT COMPLETED     187     63  
Lost to Follow-up                 3                 1  
Physician Decision                 2                 1  
Withdrawal by Subject                 2                 5  
Death                 78                 8  
Crossed Over                 0                 36  
Ongoing                 53                 2  
In Follow-up                 49                 10  

Period 2:   Crossover Phase
    GSK2118436 150 mg BID     DTIC 1000 mg/m^2 in RP; GSK2118436 in Crossover Phase  
STARTED     0     36 [1]
In Follow-up     0     11  
Ongoing     0     4  
COMPLETED     0     0  
NOT COMPLETED     0     36  
Withdrawal by Subject                 0                 1  
Death                 0                 20  
Ongoing                 0                 4  
In Follow-up                 0                 11  
[1] As of the data cut on December 18, 2012, 36 of 63 participants crossed over from DTIC to GSK2118436.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
GSK2118436 150 mg BID Participants were randomly assigned to receive oral GSK2118436 150 mg BID. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study. Participants who experienced investigator-reported DP but were benefitting from study treatment were permitted to continue GSK2118436 treatment upon approval of the GlaxoSmithKline Medical Monitor.
DTIC 1000 mg/m^2 in RP; GSK2118436 in Crossover Phase In the RP, par. received IV DTIC 1000 mg/m^2 every 3 weeks. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Par. continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study. Par. who received DTIC in the RP and experienced DP had the option, at the discretion of the Investigator, of receiving GSK2118436 150 mg BID in the Crossover Phase. Par. who permanently discontinued DTIC treatment due to an AE, withdrawal of consent, or for any reason other than DP were not eligible for crossover to GSK2118436. Crossover par. continued on GSK2118436 until further DP was noted. After DP on GSK2118436, par. were followed for response, progression, survival, and further anti-cancer therapy.
Total Total of all reporting groups

Baseline Measures
    GSK2118436 150 mg BID     DTIC 1000 mg/m^2 in RP; GSK2118436 in Crossover Phase     Total  
Number of Participants  
[units: participants]
  187     63     250  
Age  
[units: Years]
Mean ± Standard Deviation
  53.5  ± 13.76     51.6  ± 14.22     53.0  ± 13.87  
Gender  
[units: Participants]
     
Female     75     26     101  
Male     112     37     149  
Race/Ethnicity, Customized  
[units: participants]
     
White     186     63     249  
Missing     1     0     1  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival (PFS) as Assessed by the Investigator   [ Time Frame: Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months) ]

2.  Primary:   Progression-free Survival (PFS) as Assessed by an Independent Radiologist   [ Time Frame: Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months) ]

3.  Secondary:   Overall Survival   [ Time Frame: Time interval between the date of randomization and the date of death due to any cause (up to 22.1 months) ]

4.  Secondary:   Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator: Randomized Phase   [ Time Frame: From randomization until the first documented evidence of a confirmed complete response or partial response (median of 6.6 weeks) ]

5.  Secondary:   Number of Participants With a Best Overall Response of Confirmed CR or PR as Assessed by an Independent Radiologist: Randomized Phase   [ Time Frame: From randomization until the first documented evidence of a confirmed complete response or partial response (median of 12.0 weeks) ]

6.  Secondary:   Duration of Response as Assessed by the Investigator: Randomized Phase   [ Time Frame: Time from the first documented evidence of PR or CR until the first documented sign of disease progression or death due to any cause (up to 65.6 weeks) ]

7.  Secondary:   Duration of Response as Assessed by an Independent Radiologist: Randomized Phase   [ Time Frame: Time from the first documented evidence of PR or CR until the first documented sign of disease progression or death due to any cause (up to 7.4 months) ]

8.  Secondary:   Progression-free Survival (PFS2) as Assessed by the Investigator: Crossover Phase   [ Time Frame: Time from first dose of GSK2118436 in participants who crossover after initial progression to the earliest date of radiographical or photographical PD or death due to any cause (up to 6.4 months) ]

9.  Secondary:   Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator: Crossover Phase   [ Time Frame: From randomization until the first documented evidence of a confirmed complete response or partial response (up to 6.4 months) ]

10.  Secondary:   Duration of Response as Assessed by the Investigator: Crossover Phase   [ Time Frame: Time from the first documented evidence of PR or CR until the first documented sign of disease progression or death due to any cause (up to 6.4 months) ]

11.  Secondary:   Number of Participants With Non-melanoma Skin Lesions: Randomized Phase   [ Time Frame: From Screening until study completion or discontinuation from the study (up to 9.9 months) ]

12.  Secondary:   Validation of the BRAF Mutation Assay   [ Time Frame: Screening ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided by GlaxoSmithKline

Publications automatically indexed to this study:

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01227889     History of Changes
Other Study ID Numbers: 113683
Study First Received: October 21, 2010
Results First Received: June 6, 2013
Last Updated: June 12, 2014
Health Authority: Italy: AIFA - Italian Ministry of Health
France: Ministry of Health
Italy: Comitato Etico Fondazione Centro San Raffaele del Monte Tabor - Via Olgettina, 60 - 20132 Milano
Canada: Health Canada
Hungary: National Institute of Pharmacy
Spain: Ministry of Health and Consumption
Ireland: Irish Medicines Board
United States: Food and Drug Administration
Russia: Russian Ministry of Health
Poland: Ministry of Health
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
Netherlands: Medical Ethics Review Committee (METC)
Australia: Therapeutic Goods Administration